Beam Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BEAM Nasdaq 2836 beamtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beam Therapeutics Inc.

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 6:00 am
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus - Aug 5th, 2026 9:10 am
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates - Aug 4th, 2026 6:25 am
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - Aug 4th, 2026 5:00 am
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates - Jul 30th, 2026 4:00 pm
Scribe’s Genetic Editing Aims to Prevent Heart Attacks - Jul 30th, 2026 8:26 am
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 - Jul 23rd, 2026 5:00 am
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? - Jul 20th, 2026 11:50 am
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Jul 15th, 2026 8:01 am
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Jul 15th, 2026 2:53 am
Kyverna Therapeutics Sinks 13%: Here’s Why - Jul 10th, 2026 1:59 pm
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Jul 9th, 2026 2:14 pm
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Jul 9th, 2026 8:19 am
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle - Jul 8th, 2026 2:09 pm
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Jul 8th, 2026 10:47 am
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - Jul 8th, 2026 6:00 am
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Jul 8th, 2026 4:05 am
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Jul 8th, 2026 3:07 am
Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF - Jun 29th, 2026 12:55 pm
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - Jun 19th, 2026 8:35 am